What is the recommended inpatient dosing for levofloxacin (Levaquin) and vancomycin in a patient with abdominal cellulitis and urinary tract infection?

Inpatient Dosing for Levofloxacin and Vancomycin in Abdominal Cellulitis and UTI

For abdominal cellulitis with concurrent UTI, use levofloxacin 750 mg IV once daily and vancomycin 15-20 mg/kg IV every 8-12 hours (based on total body weight), targeting vancomycin trough levels of 15-20 mg/L.

Levofloxacin Dosing

The FDA-approved dosing for complicated intra-abdominal infections is levofloxacin 750 mg IV every 24 hours 1, 2. This high-dose regimen maximizes concentration-dependent bactericidal activity and provides optimal tissue penetration for abdominal infections.

For the concurrent UTI component:

• 750 mg IV once daily for 5 days is FDA-approved for complicated UTI and acute pyelonephritis 2
• This shorter, higher-dose regimen is non-inferior to traditional 10-day courses 3, 4
• The 750 mg dose achieves adequate urinary tract concentrations to treat uropathogens effectively 4

Key advantage: Levofloxacin is bioequivalent between IV and oral formulations, allowing seamless transition once the patient can tolerate oral intake 4, 5.

Vancomycin Dosing

Vancomycin 15-20 mg/kg IV every 8-12 hours (based on total body weight) 1, 6. This dosing is critical for:

• Suspected MRSA coverage in abdominal cellulitis
• Achieving target trough concentrations of 15-20 mg/L for complicated infections 6
• Optimal tissue penetration in serious skin/soft tissue infections

Important monitoring considerations:

• Measure steady-state trough level just before the fourth dose 6
• Adjust dosing based on trough levels and renal function
• For doses exceeding 1 gram, extend infusion time to 1.5-2 hours 6

Treatment Duration

• Abdominal infection: 4-7 days if adequate source control is achieved 1
• UTI component: 5 days with the 750 mg levofloxacin regimen 2, 3
• If source control is difficult or inadequate, extend therapy beyond 7 days 1

Critical Pitfalls to Avoid

1. Don't underdose vancomycin: The 15-20 mg/kg dosing is essential for complicated infections; lower doses risk treatment failure 6

2. Renal function monitoring: Both drugs require dose adjustment in renal impairment. Check baseline creatinine clearance and monitor throughout therapy 6

3. Source control is paramount: Antibiotics alone are insufficient for abdominal infections without drainage or surgical intervention when indicated 1

4. Culture-directed therapy: Obtain cultures before starting antibiotics. If resistant organisms are identified and clinical response is inadequate, adjust therapy accordingly 1

5. Fluoroquinolone resistance: If local E. coli resistance to fluoroquinolones exceeds 10-20%, consider alternative agents or await culture results before relying solely on levofloxacin for the UTI component 7, 8

Rationale for This Combination

This regimen provides:

• Gram-positive coverage (including MRSA) via vancomycin for cellulitis
• Gram-negative and anaerobic coverage via levofloxacin for intra-abdominal infection
• Urinary tract penetration with high-dose levofloxacin for concurrent UTI
• Convenience with once-daily dosing for levofloxacin, improving compliance and allowing IV-to-oral transition 4

The combination is supported by guideline recommendations for complicated intra-abdominal infections requiring broad-spectrum coverage 1, while the vancomycin component addresses potential MRSA in skin/soft tissue infections 1.